Active and refractory ulcerative proctitis: an update

• Published in: Revista medíca de Chile 2010-01, Vol.138 (1), p.109-116
• Main Authors: Caselli M, Gino, Pinedo M, George, Zúñiga D, Alvaro, Alvarez L, Manuel
• Format: Article
• Language: Spanish
• Subjects: Administration, Oral; Administration, Topical; Aminosalicylic Acids - therapeutic use; Anti-Inflammatory Agents - therapeutic use; Colitis, Ulcerative - drug therapy; Humans; Proctitis - drug therapy
• ISSN: 0034-9887

Ulcerative colitis (UC) is a chronic inflammatory disease of unknown etiology that affects a variable length of the colon, starting from the rectum. When the disease is confined to the rectum is called ulcerative proctitis (UP). Several studies have unsuccessfully attempted to determine the factors that determine the extent of involvement. The goals of therapy in UP are to induce and maintain remission of symptoms and disease. Topical treatment with 5-aminosalicylates (5-ASA) is the treatment of choice to induce remission. In the maintenance phase, long-term follow up studies suggest that treatment with 5-ASA is better than placebo, to maintain the disease inactive. For those patients that do not respond to treatment with topical 5-ASA or have a moderate to severe disease, there are additional therapies such as oral 5-ASA, topical or systemic corticosteroids, immunomodulators, biological therapies (Infliximab) and cyclosporine. Surgery is seldom needed.